Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China
Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China.
BMJ Open. 2023 Apr 12;13(4):e069703. doi: 10.1136/bmjopen-2022-069703.
Oesophageal fistula (perforation) is a devastating complication in patients with oesophageal cancer . The optimal treatment remains uncertain.
We sought to present real-world evidence on treatment modalities and survival postfistula in patients with oesophageal cancer.
DESIGN, SETTINGS AND MAIN OUTCOMES: This was a retrospective cohort study of patients with oesophageal cancer with oesophageal fistulae diagnosed between June 2010 and June 2020 in a regional cancer care centre in Zhengzhou, China (n=352). The treatment options included surgical resection, oesophageal stent grafting, gastrostomy, nasogastric tube and conservative care. The primary outcome was survival time (months) postfistula. Inverse probability of treatment weighting (IPTW) life regression was used to estimate the differences in survival time accounting for potential confounders.
The median survival time was 2.3 months (IQR: 0.7-6.0 months). Survival times were shorter in patients of male sex, T4 stage and oesophagotracheal versus oesophageal-mediastinal fistulae, and longer for any treatment option versus conservative care. The IPTW life regression analyses showed that in patients with oesophagotracheal fistulae, survival times were longer for stent grafting (+0.90 (95% CI 0.60 to 1.19) months) or gastrostomy (+0.81 (95% CI 0.47 to 1.13) months) versus nasogastric tube. In patients with oesophageal-mediastinal fistulae, survival times were shorter for stent grafting versus nasogastric tube (-0.36 (95% CI -0.63 to -0.09) months) and gastric tube (-0.29 (95% CI -0.50 to -0.08) months). Surgical resection was recorded in nine patients with oesophageal-mediastinal fistulae, and it was associated with the longest survival time in these patients.
Stent grafting or gastrostomy may be preferable to nasogastric tube in survival prognosis for patients with oesophageal cancer with oesophagotracheal fistulae. In contrast, stent grafting may be not preferable to nasogastric tube or gastrostomy in survival prognosis for patients with oesophageal-mediastinal fistulae.
食管瘘(穿孔)是食管癌患者的一种毁灭性并发症。最佳治疗方法仍不确定。
我们旨在提供食管癌患者食管瘘后治疗方式和生存的真实世界证据。
设计、地点和主要结局:这是一项回顾性队列研究,纳入 2010 年 6 月至 2020 年 6 月在中国郑州一家区域癌症治疗中心诊断为食管癌合并食管瘘的患者(n=352)。治疗选择包括手术切除、食管支架置入、胃造口术、鼻胃管和保守治疗。主要结局是瘘后生存时间(月)。采用逆概率治疗加权(IPTW)寿命回归估计生存时间的差异,以考虑潜在混杂因素。
中位生存时间为 2.3 个月(IQR:0.7-6.0 个月)。男性、T4 期、食管-气管瘘与食管-纵隔瘘患者的生存时间较短,任何治疗选择与保守治疗相比,生存时间较长。IPTW 寿命回归分析显示,对于食管-气管瘘患者,支架置入(+0.90(95%CI 0.60-1.19)个月)或胃造口术(+0.81(95%CI 0.47-1.13)个月)与鼻胃管相比,生存时间较长。对于食管-纵隔瘘患者,支架置入与鼻胃管(-0.36(95%CI-0.63 至-0.09)个月)和胃管(-0.29(95%CI-0.50 至-0.08)个月)相比,生存时间较短。9 例食管-纵隔瘘患者行手术切除,这些患者的生存时间最长。
对于食管-气管瘘患者,支架置入或胃造口术可能比鼻胃管更能改善生存预后。相比之下,对于食管-纵隔瘘患者,支架置入可能不如鼻胃管或胃造口术能改善生存预后。